HLA-A and neoplasm: Hence, A375 melanoma-bearing humanized NSG-A2 mice received two weekly boosting and three weekly vaccinations with Clec9A-targeting F-actin-TNE loaded with a pool of tumor-associated immunogenic epitopes, including the HLA-A*02 Survivin95–104, Cyclin I71–80 (RNA edited, Zhang, 2018), MAGE-A3271–279, Tyrosinase369–377, STAT1VLW, and the promiscuous HLA Class II Tyrosinase386–406 and NY-ESO-1119–143 epitopes (Figure 4C).